TY - JOUR AU - Denis, Fabrice AU - Septans, Anne-Lise AU - Le Goff, Florian AU - Jeanneau, Stephan AU - Lescure, François-Xavier PY - 2021 DA - 201/5/4 TI -通过部分封锁前后自我评估分析法国COVID-19传播源:观察研究乔- J地中海互联网Res SP - e26932六世- 23 - 5 KW - COVID-19 KW - web应用程序KW -数字医疗KW -分析KW -传输KW -法国KW -自我评估KW -锁定KW -观察KW -调查KW -影响KW -公共卫生AB -背景:我们开发了一个问卷调查在一个web应用程序分析COVID-19污染情况在法国在第二波甲流疫情。目的:本研究旨在分析法国第二次部分封锁前后对污染特征的影响，以调整公共卫生限制，进一步防止大流行激增。方法:在2020年12月15日至24日期间，在一场全国媒体宣传活动之后，向sourcecovid.fr web应用程序的用户询问了有关他们自己或近亲在2020年8月15日之后在法国受到COVID-19污染的问题。对污染情况的数据进行了评估和比较。第二次部分封锁发生在2020年10月25日，当时正值第二波大流行，并于2020年12月24日持续进行。结果:截至2020年12月24日，在web应用程序上观察到44.1万个连接。共有2218份问卷可供评估分析。约61.8% (n=1309)的参与者确定其污染来源，38.2% (n=809)的参与者认为他们知道。使用者年龄中位数为43.0岁(IQR 32-56岁)，50.7% (n=1073)为男性。评估队列的中位潜伏期为4.0天(IQR 3-5天)。 Private areas (family’s or friend’s house) were the main source of contamination (1048/2090, 50.2%), followed by work colleagues (579/2090, 27.7%). The main time of day for the contamination was the evening (339/961, 35.3%) before the lockdown and was reduced to 18.2% (86/473) after the lockdown (P<.001). The person who transmitted the virus to the user before and after the lockdown was significantly different (P<.001): a friend (382/1317, 29% vs 109/773, 14.1%), a close relative (304/1317, 23.1% vs 253/773, 32.7%), or a work colleague (315/1317, 23.9% vs 264/773, 34.2%). The main location where the virus was transmitted to the users before and after the lockdown was significantly different too (P<.001): home (278/1305, 21.3% vs 194/760, 25.5%), work (293/1305, 22.5% vs 225/760, 29.6%), collective places (430/1305, 33% vs 114/760, 15%), and care centers (58/1305, 4.4% vs 74/760, 9.7%). Conclusions: Modalities of transmissions significantly changed before and after the second lockdown in France. The main sources of contamination remained the private areas and with work colleagues. Work became the main location of contamination after the lockdown, whereas contaminations in collective places were strongly reduced. Trial Registration: ClinicalTrials.gov NCT04670003; https://clinicaltrials.gov/ct2/show/NCT04670003 SN - 1438-8871 UR - //www.mybigtv.com/2021/5/e26932 UR - https://doi.org/10.2196/26932 UR - http://www.ncbi.nlm.nih.gov/pubmed/33878018 DO - 10.2196/26932 ID - info:doi/10.2196/26932 ER -